Plain-English translation of NCT05653011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying inflammatory bowel disease (IBD)—a chronic condition that causes inflammation in the digestive tract—to understand why some patients respond well to TNF-alpha inhibitor medications while others don't. By collecting blood and tissue samples from people with IBD and comparing them to healthy controls, the team hopes to identify biological markers that can predict which patients will benefit most from this treatment.
IBD is a lifelong condition that's hard to cure, and patients can improve for a while and then get worse again. Right now, doctors struggle to predict which patients will respond well to treatment before starting it. This study aims to find biological clues that could help doctors choose the best treatment for each patient from the start.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a tissue sample collected during a routine colonoscopy and will also provide a blood sample. The research team will compare your samples to those from other IBD patients and healthy volunteers to look for patterns that might predict treatment success. The study is observational, meaning you won't be given any new medications as part of the research—researchers are simply looking for biological markers in samples you provide.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
South Korea
Sponsor
Seoul National University Bundang Hospital
Enrollment target
~100 participants
Started
March 2013
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yu kyung Jun, M.D., Ph.D
Seoul National University Bundang Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.